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equally improve endothelial function in patients
with type 2 diabetes: EDGE study
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Background: Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of
cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Dipeptidyl peptidase 4 (DPP-4)
inhibitors also attenuate PPH. PPH is one of the factors leading to endothelial dysfunction which is an early event
in the pathogenesis of atherosclerosis. Furthermore, DPP-4 inhibitors protect endothelial function through a
GLP-1-dependent mechanism. However, the impact of these two types of drugs on endothelial dysfunction
in patients with type 2 diabetes has not been fully elucidated. We compared the effects of sitagliptin, a DPP-4
inhibitor, and voglibose, an alpha GI, on endothelial function in patients with diabetes.
Methods: We conducted a randomized prospective multicenter study in 66 patients with type 2 diabetes who
did not achieve the treatment goal with sulfonylurea, metformin or pioglitazone treatment; 31 patients received
sitagliptin treatment and 35 patients, voglibose treatment. The flow-mediated dilatation (FMD) of the brachial
artery was measured in the fasting state at baseline and after 12 weeks of treatment. The primary endpoint was
a change in FMD (ΔFMD) from the baseline to the end of follow-up. The effects of sitagliptin and voglibose
on FMD were assessed by ANCOVA after adjustment for the baseline FMD, age, sex, current smoking, diabetes
duration and body mass index. Secondary efficacy measures included changes in HbA1c, GIP, GLP-1, C-peptide,
CD34, lipid profile, oxidative stress markers, inflammatory markers and eGFR and any adverse events.
Results: ΔFMD was significantly improved after 12 weeks of treatment in both groups, and there was no
significant difference in ΔFMD between the two groups. There were no significant differences in changes in
HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between
the two groups. Compared with voglibose, sitagliptin significantly increased the circulating CD34, a marker of
endothelial progenitor cells. Adverse events were observed in 5 patients in only the voglibose group (diarrhea 1,
nausea 1, edema 2 and abdominal fullness 1).
Conclusions: Sitagliptin improved endothelial dysfunction just as well as voglibose in patients with type 2
diabetes. Sitagliptin had protective effects on endothelial function without adverse events.
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Postprandial hyperglycemia (PPH) plays a major role in
cardiovascular complications in patients with type 2
diabetes [1] and impaired glucose tolerance (IGT) [2].
PPH is one of the main factors leading to endothelial
dysfunction, which is an early event in the pathogenesis
of atherosclerosis [3,4].
Alpha glucosidase inhibitor (GI) prevents the digestion
of carbohydrates including starch and table sugar, atten-
uates postprandial hyperglycemia [5] and delays the
development of type 2 diabetes in patients with IGT [6].
Miglitol, an alpha GI, improves endothelial dysfunction
assessed by the response of forearm blood flow to react-
ive hyperemia and flow-mediated dilatation (FMD) in
patients with type 2 diabetes and coronary artery disease
[7,8]. Acarbose, an alpha GI, improves postprandial endo-
thelial dysfunction in patients with type 2 diabetes [9,10]
and reduces the risk of cardiovascular events in patients
with type 2 diabetes [11] and IGT [12,13].
Dipeptidyl peptidase 4 (DPP-4) inhibitor enhances en-
dogenous incretin action and promotes glucose-dependent
insulin secretion. Thus, DPP-4 inhibitor attenuates post-
prandial hyperglycemia [14]. Furthermore, glucagon-like
peptide-1 (GLP-1), an incretin, induces an endothelial-
dependent relaxation via NO-dependent action [15] and
improves endothelial dysfunction in patients with type 2
diabetes [16], and sitagliptin, a DPP-4 inhibitor, protects
endothelial function in spontaneously hypertensive rats
through a GLP-1-dependent mechanism [17]. However, the
impact of these two types of drugs on endothelial dys-
function in patients with type 2 diabetes has not been
fully elucidated and has been controversial [18,19].
We conducted a randomized prospective multicenter
study to compare the effects of sitagliptin, a DPP-4 inhibi-
tor, and voglibose, an alpha GI, on endothelial function
assessed by FMD in patients with type 2 diabetes.
Liao et al. reported that number of circulating endo-
thelial progenitor cells (EPCs) in patients with type 2
diabetes was significantly lower than that in the healthy
subjects, treatment with metformin significantly in-
creased EPCs and the EPCs number was related to
endothelial function assessed by FMD [20]. Fadini et al.
reported that sitagliptin increased circulating EPCs in
type 2 diabetic patients [21]. We also compared the ef-
fects of sitagliptin and voglibose on number of circulat-
ing EPCs assessed by measurement of CD34, a maker of
EPCs [22], postive cells in patients with type 2 diabetes
in this study.
DPP-4 inhibitors have anti-inflammatory and anti-
oxidative effects [23-25]. Ishibashi et al. reported that
linagliptin inhibited the generation of reactive oxygen
species induced by advanced glycation end products
(AGEs) in endothelial cells [23]. Matsubara et al. re-
ported that sitagliptin improves endothelial dysfunctionin association with ant-inflammatory effects in patients
with coronary artery disease and uncontrolled diabetes
[24]. Shiraki et al. reported that GLP-1 reduced TNF-α-
induced oxidative stress in endothelial cells [25]. We
also measured levels of inflammatory markers, includ-
ing high-sensitivity C-reactive protein (hs-CRP) and
pentraxin-3 (PTX-3), and oxidative stress markers, in-
cluding malondialdehyde-modified low-density lipopro-
tein (MDA-LDL) and urine 8-hydroxy-2’-deoxyguanosine
(8-OHdG).
The primary endpoint in this study was a sitagliptin-
or voglibose-induced change in FMD (ΔFMD) from
baseline to the end of follow-up. Secondary efficacy
measures included changes in HbA1c, gastric inhibitory
peptide (GIP), GLP-1, C-peptide, CD34, lipid profile,
adiponectin, oxidative stress markers including MDA-LDL
and urine 8-OHdG, inflammatory markers including hs-
CRP and PTX-3, and estimated glomerular filtration rate
(eGFR) and any adverse events.
Methods
Study populations
We conducted a randomized prospective multicenter
study in patients with type 2 diabetes who did not
achieve the treatment goal with diet, exercise, sulfonyl-
urea, metformin or pioglitazone treatment. We recruited
66 patients (men and women) who were from 20 to
85 years of age. Thirty-one patients received the sitaglip-
tin (50 mg/day) treatment and 35 patients, the voglibose
(0.6 mg/day) treatment. The doses of the two drugs used
in this study are recommended therapeutic doses for
Japanese [26,27] and the doses are covered by the Japanese
National Health Insurance. The exclusion criteria were
as follows: treatment with insulin, alpha GI or glinide,
type 1 diabetes, HbA1c ≥ 9.0%, systolic blood pres-
sure ≥ 160 mmHg and serum creatinine ≥ 1.5 mg/dL at
baseline. The study protocol was approved by the Ethics
Committee of Okayama University Graduate School of
Medicine, Dentistry, and Pharmaceutical Sciences, and
written informed consent was obtained from all patients
before any study procedure was undertaken.
Study protocol
The patients were followed for at least 8 weeks to con-
firm that they did not achieve the treatment goal with
diet, exercise, sulfonylurea, metformin or pioglitazone
treatment. The patients were prospectively randomly
assigned to additional treatment with either sitagliptin
(50 mg/day) or voglibose (0.6 mg/day) for 12 weeks
(Figure 1). The flow-mediated dilatation (FMD) of the
brachial artery was measured in the fasting state at
baseline and after 12 weeks of the treatment. Blood
and urine tests were also performed at baseline and at
the end of the study. The patients’ antihypertensive,
Figure 1 Study protocol. The patients were followed for at least 8 weeks to confirm that they did not achieve the treatment goal. The
patients were prospectively, randomly assigned to additional treatment with either sitagliptin (50 mg/day) or voglibose (0.6 mg/day) for
12 weeks. Measurements of flow-mediated dilatation (FMD) of the brachial artery and blood and urine tests were performed in the fasting
state at baseline and after 12 weeks of treatment.
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changed and anti-oxidant drugs, including vitamin C
and E, were not added throughout the study period.
Measurements of biochemical parameters
The following parameters were measured at baseline and
after 12 weeks of treatment: complete blood count, liver
function test including measurement of AST, ALT and
LDH, renal function test including measurement of
BUN, creatinine, Na, K and Cl, HbA1c, gastric inhibitory
peptide (GIP), GLP-1, C-peptide, CD34, lipid profile includ-
ing total cholesterol, triglyceride, and high-density lipo-
protein (HDL-C), adiponectin, oxidative stress markers
including MDA-LDL and urine 8-OHdG, inflammatory
markers including hs-CRP and PTX-3, and estimated
glomerular filtration rate (eGFR). HbA1c levels were
measured using high-performance liquid chromatog-
raphy. The number of CD34+ cells was determined by
flow cytometry using FITC-labeled CD45 and phyco-
erythrin (PE)-labeled CD34 antibodies (BD Biosciences).
eGFR (mL/min/1.73 m2) was determined by the modi-
fied Modification of Diet and Renal Disease study for-
mula (MDRD) for Japanese: eGFR = 194 × (age-0.287) ×
(serum creatinine-1.094) × (0.739 if female) [28]. These
measurements were performed by SRL Company, Ltd.
(Tokyo, Japan).
Flow-mediated dilation (FMD)
Endothelium-dependent dilation was assessed as a par-
ameter of vasodilation according to the guidelines for
ultrasound assessment of FMD of the brachial artery in
the fasting state [29]. Using a 10-MHz linear-array
transducer probe (Unex Company Ltd., Nagoya, Japan),longitudinal images of the brachial artery at baseline
were recorded with a stereotactic arm, and measurements
of the artery diameter were made after supine rest for
≥5 min as previously described [30-32]. The diameter of
the artery was measured from clear anterior (media-adven-
titia) and posterior (intima-media) interfaces, which were
manually determined. Then, suprasystolic compression
(50 mmHg higher than systolic blood pressure) was per-
formed at the right forearm for 5 min, and measurements
of the artery diameter were made continuously from
30 sec before to ≥2 min after cuff release. Maximum
vasodilation was then evaluated from the change in ar-
tery diameter after the release of occlusion (%FMD).
FMD is known to be affected by a wide range of bio-
logical, environmental, and methodological factors
[33]. To quantify inter- and intra-observer reproducibility,
baseline brachial diameter and FMD were measured by
three individuals in Okayama University Hospital. Inter-
and intra-observer coefficients were high (r > 0.90).
Statistical analysis
The results are expressed as mean ± SD. We assumed
that FMD increased by 2% in sitagliptin group and
decreased by 0.5% in voglibose group with a standard
deviation of 3%. A minimum sample size of 24 partici-
pants in each group was required to detect statistical
differences in FMD with a power of 80% and α error of
5%. The effects of sitagliptin and voglibose on FMD
were assessed by ANCOVA after adjustment for the
baseline FMD, age, sex, current smoking, diabetes
duration and body mass index (BMI). Differences in
age, sex, BMI and abdominal girth were compared
using Student’s t-test. The duration of diabetes was
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egorical variables, using Fisher’s exact test. Differences
in secondary efficacy measures between baseline and
12 weeks were compared using the paired Student’s t-




Although 66 patients with type 2 diabetes were enrolled
in this study between September 2010 and December
2011, 6 patients were excluded from this study (4 proto-
col violation at baseline and 2 withdrawal of consent).
During the follow-up period, 5 patients with hyperten-
sion dropped out of the study due to change of con-
comitant antihypertensive drugs. The follow-up study
was completed in 55 (83%) of the patients; 24 patients
received the sitagliptin treatment and 31 patients, the
voglibose treatment. The data collection was completed
in July 2012. Baseline characteristics, including age, sex,
BMI and the type of anti-diabetic medication are shown
in Table 1. It has been reported that endothelium-
dependent vasodilation assessed by FMD declines with
advance of age [34,35]. We recruited men and women
who were from 20 to 85 years of age. The age range was
quite wide in our study, but there was no significant dif-
ference in age or baseline FMD between the two groups
(age, sitagliptin: 66.6 ± 11.9, >70 years: 12, median 69.5,
range: 37 – 84 versus voglibose: 68.4 ± 9.2, >70 years:
14, median 70.0, range: 48 – 80 years old, P = 0.529,
Table 1) (baseline FMD, sitagliptin: 5.41 ± 2.25 versus
voglibose: 4.96 ± 2.16%, P = 0.450, Table 2). We did not
exclude patients with severe dyslipidemia, but there
were no significant differences in use of antihyperlipi-
demic drugs (Table 1) and baseline total cholesterol,
triglyceride and HDL-C (Table 3) between the two groups.
No patients died, developed cardiovascular events or were
admitted to the hospital during the course of the study.
The primary endpoint
Change in FMD (ΔFMD) was significantly improved after
12 weeks of treatment in both groups (sitagliptin: +1.11,
95% CI: 0.07-2.16 versus voglibose: +0.98, 95% CI:
0.04-1.91), and there was no significant difference in
ΔFMD between the two groups (Table 2 and Figure 2).
Secondary efficacy measures
There were no significant differences in changes in
HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative
stress marker, inflammatory marker and eGFR between
the two groups (Table 3). Sitagliptin tended to increase
GLP-1 levels after 12 weeks of treatment (0 week: 5.71 ±
5.92 versus 12 weeks: 8.25 ± 6.37 pmol/L, P = 0.0611), but
voglibose did not change the levels (0 week: 6.65 ±10.18 versus 12 weeks: 6.66 ± 6.15 pmol/L, P = 0.9973).
Compared with voglibose, sitagliptin significantly increased
circulating CD34, a marker of positive endothelial progeni-
tor cells (P < 0.05) (Table 3 and Figure 3).
Adverse events
Adverse events were observed in 5 patients in the vogli-
bose group (Table 4). There were no serious side effects
in either group.
Discussion
In summary, ΔFMD was significantly improved after
12 weeks of treatment in both the sitagliptin and vogli-
bose groups, and there was no significant difference in
ΔFMD between the two groups.
Alpha GI improves postprandial endothelial dysfunc-
tion in patients with type 2 diabetes [9,10]. We showed
that not only voglibose, an alpha GI, but also sitaglip-
tin, a DPP-4 inhibitor, improves endothelial function
as assessed by FMD in patients with type 2 diabetes.
The impact of a DPP-4 inhibitor on endothelial
dysfunction in patients with type 2 diabetes is contro-
versial. A recent study showed that sitagliptin improved
endothelial dysfunction assessed by the reactive hyperemia
arterial tonometry index (RHI) after 6 months of treat-
ment in patients with diabetes and coronary artery disease
[24]. We also showed that sitagliptin improved endothelial
dysfunction assessed by another method, FMD. A pro-
spective observational single arm trial also showed that
the treatment with sitagliptin for 12 weeks increased FMD
in patients with type 2 diabetes [36]. Here, we conducted
a randomized prospective multicenter study in patients
with type 2 diabetes and revealed improvement of FMD
after the 12-week treatment with sitagliptin. In contrast,
another short-term study showed that DPP-4 inhibitors,
including sitagliptin or alogliptin, attenuated endothelial
function as evaluated by FMD after 6 weeks of treatment
in patients with diabetes [19]. Furthermore, voglibose, an
alpha GI, did not affect FMD in the study. Therefore,
short-term treatment with either DPP-4 inhibitors or
alpha GI does not ameliorate endothelial dysfunction in
patients with diabetes. Our study showed that 12-week
treatment with either sitagliptin or voglibose ameliorated
endothelial function. Thus, at least 12 weeks of treatment
is needed to improve endothelial function.
The STOP-NIDDM trial showed that an alpha GI re-
duces the risk of cardiovascular events in patients with
IGT [12]. DPP-4 inhibitors are also expected to have
beneficial cardiovascular effects [37,38]. However, two
recent trials with DPP-4 inhibitors, SAVOR-TIMI 53
and EXAMINE trials, showed that saxagliptin and alo-
gliptin did not increase or decrease ischemic events in
patients with type 2 diabetes [39,40]. These trials dem-
onstrated the safety of DPP-4 inhibitors but did not






Age, y 66.6 ± 11.9 68.4 ± 9.2 0.529
Male 10 (41.7%) 18 (58.1%) 1.000
Diabetes duration, m 57.6 ± 41.2 41.9 ± 44.1 0.075
BMI, kg/m2 27.8 ± 3.5 25.7 ± 4.3 0.061
Abdominal girth, cm 91.4 ± 11.1 85.6 ± 17.4 0.303
Current smoking 5 (20.8%) 5 (16.1%) 0.475
Regular alcohol
drinkers
4 (16.7%) 9 (29.0%) 0.349
Diabetic complication 1 (4.2%) 2 (6.5%) 1.000
Diabetic retinopathy 1 (4.2%) 0 (0%) 0.436
Diabetic nephropathy 0 (0%) 2 (6.5%) 0.499
Diabetic neuropathy 0 (0%) 0 (0%) -
Hypertension 20 (83.3%) 25 (80.6%) 1.000
Hyperlipidemia 15 (62.5%) 18 (58.1%) 0.787
Hyperuricemia 4 (16.7%) 2 (6.5%) 0.387
Renal disturbance 3 (12.5%) 2 (3.2%) 0.307
Established Cardiovascular
diseases
7 (29.2) 7 (22.6) 0.756
Cerebrovascular disease 4 (16.7%) 1 (3.2%) 0.156
Myocardial infarction 3 (12.5%) 5 (16.1%) 1.000
Peripheral artery disease 2 (8.3%) 1 (3.2%) 0.575
Antidiabetic drugs
Pioglitazone 11 (45.8) 16 (51.6%) 0.787
Sulfonylurea 5 (20.8%) 3(9.7%) 0.276
Metformin 3 (12.5%) 0 (0%) 0.077
Antihypertensive drugs
ARB 15 (62.5%) 19 (61.3%) 1.000
CCB 13 (54.2%) 18 (58.1%) 0.791
Diuretics 9 (37.5%) 10 (32.3%) 0.778
Others 11 (45.8%) 12 (38.7%) 0.783
ACE-I 1 (4.2%) 3 (9.7%)
α-Blocker 4 (16.7%) 3 (9.7%)
β-Blocker 3 (12.5%) 5 (16.1%)
αβ-Blocker 1 (4.2%) 1 (3.2%)
Aldosterone antagonist 2 (8.3%) 0 (0%)
Antihyperlipidemic drugs 2 (8.3%) 0 (0%)
Statins 12 (50.0%) 14 (45.2%) 0.789
Fibrate 2 (8.3%) 2 (6.5%) 1.000
Ezetimibe 3 (12.5%) 6 (19.4%) 0.716
Eicosapentaenoic acid 2 (8.3%) 3 (9.7%) 1.000
Antithrombogenic agents
Antiplatelet agent 16 (66.7%) 17 (54.8%) 0.417
Anticoagulant agent 2 (8.3%) 0 (0.0%) 0.186
Others
Table 1 Baseline clinical characteristics (Continued)
Nitrates 3 (12.5%) 0 (0%) 0.077
Allopurinol 1 (4.2%) 1 (3.2%) 1.000
Uricosuric agents 0 (0%) 1 (3.2%) 1.000
ARB: angiotensin receptor blocker, CCB: calcium channel blocker, ACE-I:
Angiotensin-converting enzyme inhibitor. Data are expressed as mean ± SD or
as a number (percentage).
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patients for cardiovascular disease were enrolled in those
studies. In the SAVOR-TIMI 53 trial, about 78% of the
patients had established cardiovascular disease, and the
EXAMINE trial consisted of patients with acute cor-
onary syndrome. Mean HbA1c levels were about 8.0
in patients of those studies. Our study included rela-
tively low-risk patients. Only about 25% of the pa-
tients in our study had established cardiovascular
diseases. Mean HbA1c levels were about 7.0. ΔFMD
was significantly improved after 12 weeks of treat-
ment in both the sitagliptin and voglibose groups in
our study. The clinical implication of this study is
the demonstration of beneficial effects of both sita-
gliptin and voglibose on endothelial dysfunction in
low-risk and mild-risk patients with type 2 diabetes.
Therefore, sitagliptin and voglibose might have cardio-
vascular benefits in low-risk and mild-risk patients
with type 2 diabetes. Further studies are needed to
clarify the long-term benefits for cardiovascular dis-
ease [37].
Iwamoto et al. reported that once-daily sitagliptin
monotherapy (50 mg/day) showed greater efficacy
and better tolerability than did thrice-daily voglibose
(0.6 mg/day) over 12 weeks in Japanese patients with
type 2 diabetes [41], but there was no significant differ-
ence in changes in HbA1c between the sitagliptin
(50 mg/day) and voglibose (0.6 mg/day) groups in ourTable 2 Changes in FMD (ΔFMD) in the sitagliptin and
voglibose group
Variable Sitagliptin Voglibose Between-group
differencen = 24 n = 31
FMD (%)
Baseline at 0 W 5.41 ± 2.25 4.96 ± 2.16 P = 0.450
at 12 W 6.17 ± 2.00 5.94 ± 2.15 P = 0.692
ΔFMD:12 W-0 W 0.76 ± 2.42 0.98 ± 2.41 P = 0.729
Adjusted ΔFMD:12 W-0 W* 1.11 0.98 P = 0.8316
(95% CIs) (0.07-2.16) (0.04-1.91)
Values are means ± SD or the least square means (95% CI). *The least square
means (95% CIs) were derived from ANCOVA adjusted for the baseline FMD,
age, sex, current smoking, diabetes duration and BMI.
Table 3 Changes in secondary efficacy measures in the sitagliptin and voglibose groups
Sitagliptin Voglibose Between-group difference
Variable mean ± SD P value mean ± SD P value P value
HbA1C
baseline at 0 W 7.04 ± 0.56 6.94 ± 0.45
at 12 W 6.65 ± 0.57 6.59 ± 0.45
12 W-0 W −0.39 ± 0.60 0.0051 −0.35 ± 0.39 <0.0001 0.8021
GIP
baseline at 0 W 289.92 ± 326.04 214.21 ± 220.15
at 12 W 246.50 ± 284.25 258.41 ± 226.88
12 W-0 W −43.42 ± 190.10 0.3077 44.20 ± 198.54 0.2671 0.1323
GLP-1
baseline at 0 W 5.71 ± 5.92 6.65 ± 10.18
at 12 W 8.25 ± 6.37 6.66 ± 6.15
12 W-0 W 2.54 ± 5.71 0.0611 0.00 ± 5.70 0.9973 0.1418
C-peptide
baseline at 0 W 3.913 ± 2.567 3.037 ± 1.629
at 12 W 3.909 ± 2.410 3.571 ± 2.710
12 W-0 W −0.003 ± 1.366 0.9906 0.534 ± 2.712 0.2977 0.3555
CD34
baseline at 0 W 0.956 ± 0.563 0.896 ± 0.622
at 12 W 1.134 ± 0.615 0.847 ± 0.470
12 W-0 W 0.178 ± 0.379 0.0311 −0.050 ± 0.368 0.4656 0.0304
Total cholesterol
baseline at 0 W 181.6 ± 28.8 187.8 ± 38.9
at 12 W 172.5 ± 28.2 183.9 ± 46.6
12 W-0 W −9.0 ± 21.5 0.0509 −3.9 ± 30.0 0.4865 0.4807
Triglyceride
baseline at 0 W 158.9 ± 131.1 141.2 ± 68.4
at 12 W 122.4 ± 60.9 119.2 ± 51.9
12 W-0 W −36.5 ± 98.8 0.0837 −22.1 ± 52.0 0.0249 0.5217
HDL-C
baseline at 0 W 56.4 ± 16.8 53.8 ± 13.0
at 12 W 57.5 ± 24.4 50.3 ± 11.4
12 W-0 W 1.0 ± 20.9 0.8096 −3.5 ± 8.3 0.0246 0.3223
adiponectin
baseline at 0 W 13.80 ± 12.88 15.15 ± 13.81
at 12 W 13.11 ± 11.10 14.09 ± 8.76
12 W-0 W −0.69 ± 2.71 0.2260 −1.06 ± 7.41 0.4413 0.8020
MDA-LDL
baseline at 0 W 98.7 ± 32.0 112.4 ± 44.3
at 12 W 99.7 ± 44.5 116.6 ± 49.7
12 W-0 W 1.0 ± 33.8 0.8812 4.2 ± 45.0 0.6156 0.7787
8-OHdG
baseline at 0 W 12.20 ± 6.55 12.31 ± 8.88
at 12 W 13.10 ± 7.39 12.43 ± 15.46
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Table 3 Changes in secondary efficacy measures in the sitagliptin and voglibose groups (Continued)
12 W-0 W 0.90 ± 7.30 0.5533 0.12 ± 17.29 0.9699 0.8252
hs-CRP
baseline at 0 W 2194.4 ± 4079.1 2052.2 ± 3816.2
at 12 W 1202.0 ± 1424.2 3322.7 ± 7813.6
12 W-0 W −992.4 ± 3609.6 0.1911 1270.5 ± 5592.1 0.2233 0.0783
PTX-3
baseline at 0 W 1.606 ± 0.733 2.461 ± 2.989
at 12 W 1.491 ± 0.585 1.848 ± 0.790
12 W-0 W −0.115 ± 0.462 0.2334 −0.613 ± 2.542 0.1967 0.3012
e-GFR
baseline at 0 W 66.8 ± 20.8 63.6 ± 20.8
at 12 W 62.2 ± 17.8 61.4 ± 19.9
12 W-0 W −4.6 ± 9.7 0.0301 −2.1 ± 7.7 0.1306 0.3007
GIP: gastric inhibitory peptide, GLP-1: glucagon-like peptide-1, HDL-C: high density lipoprotein cholesterol, MDA-LDL: malondialdehyde-modified low density
lipoprotein, 8-OHdG: 8-hydroxy-2’-deoxyguanosine, hs-CRP: high-sensitivity C-reactive protein, PTX-3: pentraxin-3, e-GFR: estimated glomerular filtration rate.
Data are expressed as mean ± SD.
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study and our study were about 7.8 and 7.0, respect-
ively. Lower HbA1c at baseline in our study might have
had an influence on changes in HbA1c levels. Sitaglip-
tin tended to increase GLP-1 levels after 12 weeks of
treatment, but there was no significant difference inFigure 2 Adjusted changes in FMD (ΔFMD) in the sitagliptin and vogl
square means (95% CIs) were derived from ANCOVA adjusted for the ba
ΔFMD was significantly improved after 12 weeks of treatment in both g
the two groups.changes in GIP and GLP-1 between the two groups in
this study. These results might be because of the small
sample size.
Matsubara et al. reported that treatment with sitaglip-
tin for 6 months improved endothelial dysfunction along
with a decrease in hs-CRP in patients with coronaryibose groups. Values are the least square means (95% CI). The least
seline FMD, age, sex, current smoking, diabetes duration and BMI.
roups, and there was no significant difference in ΔFMD between
Figure 3 Changes in CD34 in the sitagliptin and voglibose groups. A. Circulating CD34 levels at 0 week and 12 weeks in the sitagliptin
and voglibose groups. *P < 0.05 vs. 0 W, paired t-test. B. Change in CD34 from the baseline to the end of follow-up (ΔCD34). **P < 0.05,
Student’s t-test.
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profiles and eGFR did not change after treatment with
sitagliptin in that study as well as in our study. Our
study showed no significant difference in changes in
hs-CRP after treatment with sitagliptin. Furthermore,
Sakamoto et al. reported that sitagliptin improved
blood pressure and lipid profiles in patients with type 2
diabetes [42]. These different results might be due to
the small sample size, short-term treatment or study in
low risk patients with type 2 diabetes.
Fadini et al. reported that sitagliptin increased cir-
culating EPCs in type 2 diabetic patients with con-
comitant upregulation of stromal-derived factor-1α
(SDF-1α) [21]. SDF-1α is a chemokine that stimu-
lates bone marrow mobilization of EPCs and is one
of the substrates of DPP-4. We also showed that
sitagliptin significantly increased circulating CD34,
but voglibose did not increase CD34. Therefore, this
is an ancillary effect of sitagliptin and it is independ-
ent from blood glucose levels. Liao et al. reported
that the number of EPCs was an independent riskTable 4 Adverse events
Events Sitagliptin Voglibose
n = 29 n = 34
Diarrhea 0 (0%) 1 (2.9%)
Nausea 0 (0%) 1 (2.9%)
Edema 0 (0%) 2 (5.9%)
Abdominal fullness 0 (0%) 1 (2.9%)
Number of cases (%) is shown.factor for FMD [20]. Thus, this effect might be fa-
vorable for the preservation of endothelial function
in the future. Further long-term studies are needed
to clarify this point.
A recent study revealed that alogliptin, a DPP-4 inhibi-
tor, did not increase the frequency of serious adverse
events, including hypoglycemia, cancer, pancreatitis,
and initiation of dialysis in patients with type 2 dia-
betes who had a recent acute coronary syndrome [40].
A pooled analysis of 25 randomized clinical trials did
not indicate that treatment with sitagliptin increases
cardiovascular risk in patients with type 2 diabetes
mellitus [43]. Our study also showed that sitagliptin
did not cause serious adverse events. Thus, DPP-4
inhibitors may be safe drugs for patients with type 2
diabetes.Study limitations
The first limitation of this study was the small sizes of
the groups. The second was heterogeneity of the popula-
tion in this study. The age range was quite wide in our
study. The third limitation was that our study was a
short-term study. Our findings need to be confirmed in
a large cohort of patients with type 2 diabetes and with
a long period.
In conclusion, sitagliptin improves endothelial dys-
function just as well as voglibose in patients with type
2 diabetes. Furthermore, sitagliptin increases the level
of circulating CD34. Sitagliptin has protective effects
on endothelial function without adverse events. These
effects have potential favorable cardiovascular implica-
tions for patients with type 2 diabetes.
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